Results 61 to 70 of about 268,751 (268)

Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG

EJNMMI Research, 2020
Background In order to study the CXCR4 expression with [68Ga]pentixafor PET in different types of non-Hodgkin lymphoma, we performed a retrospective study to describe the [68Ga]pentixafor PET/CT imaging in a spectrum of lymphomas and to compare it with ...
Qingqing Pan, Yaping Luo, Yan Zhang, Long Chang, Ji Li, Xinxin Cao, Jian Li, Fang Li   +7 more
doaj   +1 more source

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy

Haematologica, 2018
Mantle cell lymphoma (MCL), an aggressive B-cell malignancy accounting for 6% of non-Hodgkin lymphomas, remains incurable with standard therapy. Despite the approval of bortezomib,[1][1] temsirolimus,[2][2] lenalidomide,[3][3] ibrutinib[4][4] and ...
T. Eyre, H. Walter, S. Iyengar, G. Follows, M. Cross, C. Fox, A. Hodson, Josh T. Coats, S. Narat, N. Morley, M. Dyer, G. Collins   +11 more
semanticscholar   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.

Journal of Clinical Oncology, 2019
PURPOSE Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, the benefit ...
J. Gerson, E. Handorf, D. Villa, A. Gerrie, Parv Chapani, Shaoying Li, L. Medeiros, Michael Wang, Jonathon B. Cohen, O. Calzada, M. Churnetski, B. Hill, Y. Sawalha, F. Hernandez-Ilizaliturri, S. Kothari, J. Vose, M. Bast, T. Fenske, Swapna Narayana Rao Gari, K. Maddocks, D. Bond, V. Bachanova, B. Kolla, J. Chavez, B. Shah, F. Lansigan, T. Burns, Alexandra M. Donovan, N. Wagner-Johnston, M. Messmer, A. Mehta, J. Anderson, N. Reddy, Alexandra E. Kovach, D. Landsburg, M. Glenn, D. Inwards, R. Karmali, J. Kaplan, P. Caimi, S. Rajguru, A. Evens, A. Klein, Elvira Umyarova, Bhargavi Pulluri, J. Amengual, J. Lue, C. Diefenbach, R. Fisher, S. Barta   +49 more
semanticscholar   +1 more source

Optimizing Markers for Chronic Lymphocytic Leukemia Diagnosis by Flow Cytometry: Results From the Nationwide Thai Lymphoma Study Group

Journal of Clinical Laboratory Analysis, EarlyView.
Our study proposed a practical set of customized flow cytometry markers that enhance the diagnosis of CLL by improving both sensitivity and accuracy. Moreover, these markers hold significant prognostic value. The identification of relapse‐associated markers provides critical insights to inform personalized treatment and monitoring strategies.
Ornnicha Sathitakorn, Sirorat Kobbuaklee, Chantiya Chanswangphuwana, Thanawat Rattanathammethee, Nisa Makruasi, Anothai Chintabanyat, Suporn Chuncharunee, Pisa Phiphitaporn, Archrob Khuhapinant, Peerapon Wong, Jakrawadee Julamanee, Chayapa Thookhamme, Lalita Norasetthada, Udomsak Bunworasate, Kitsada Wudhikarn, Tanin Intragumtornchai, Chantana Polprasert   +16 more
wiley   +1 more source

Application of Physiologically‐Based Pharmacokinetic Modeling to Support Drug Labeling: Prediction of CYP3A4‐Mediated Pirtobrutinib‐Drug Interactions

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Pirtobrutinib is a reversible Bruton tyrosine kinase (BTK) inhibitor. In vitro, pirtobrutinib is metabolized by cytochrome P450 (CYP) 3A4 and uridine 5′‐diphosphoglucuronosyl transferases (UGTs) and causes reversible and time‐dependent inhibition and induction of CYP3A4.
Dan‐Dan Tian, Stephen D. Hall, Sonya C. Chapman, Maria M. Posada   +3 more
wiley   +1 more source

Characteristics of follicular and mantle cell lymphoma in Brazil: prognostic impact of clinical parameters and treatment conditions in two hospitals

Hematology, Transfusion and Cell Therapy, 2018
Objective: Follicular and mantle cell lymphoma are low-grade B-cell malignancies that lack good responses to chemoimmunotherapy. This study aimed to assess retrospectively clinicopathological features and to determine independent prognostic factors for ...
Guilherme Rossi Assis-Mendonça, André Henrique Crepaldi, Márcia Torresan Delamain, Adriana Helena Moreira, Felipe D’Almeida Costa, Vladmir Cláudio Cordeiro de Lima, Cármino Antonio de Souza, Fernando Augusto Soares, José Vassallo   +8 more
doaj   +1 more source

CRISPR Technology in Disease Management: An Updated Review of Clinical Translation and Therapeutic Potential

Cell Proliferation, EarlyView.
CRISPR‐Cas systems offer transformative genome editing capabilities for precise manipulation of cellular genes. This enables two main therapeutic avenues: ex vivo modification of patient cells for re‐transplantation or direct in vivo gene targeting via advanced delivery methods.
Bahareh Farasati Far, Marziyeh Akbari, Mohammad Amin Habibi, Morteza Katavand, Sherko Nasseri   +4 more
wiley   +1 more source

Acute dyspnoea and single tracheal localisation of mantle cell lymphoma

Journal of Hematology & Oncology, 2010
Background Mantle cell lymphoma is a lymphoid entity characterized by adenopathy, blood and bone marrow involment which only recurrent mucosal localisation is the lymphomatoid polyposis. Few other mucosal infiltrations have been already reported. Results
Quintin-Roué Isabelle, Morel Frederic, André Norbert, Eveillard Jean-Richard, Tempescul Adrian, Ianotto Jean-Christophe, Berthou Christian   +6 more
doaj   +1 more source

Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options?

European Journal of Haematology, EarlyView.
ABSTRACT Mantle Cell Lymphoma (MCL) is an aggressive B‐cell non‐Hodgkin lymphoma characterized by the hallmark t(11;14)(q13;q32) translocation, resulting in cyclin D1 overexpression. Predominantly affecting elderly males, MCL exhibits marked clinical and biological heterogeneity, ranging from indolent SOX11‐negative variants to highly proliferative ...
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source